| 王 俊,冉凤鸣,钱 羽.甲磺酸伏美替尼治疗非小细胞肺癌的研究进展[J].肿瘤学杂志,2024,30(9):715-721. |
| 甲磺酸伏美替尼治疗非小细胞肺癌的研究进展 |
| Research Progress on Furmonertinib in Treatment of Non-Small Cell Lung Cancer |
| 投稿时间：2024-03-11 |
| DOI：10.11735/j.issn.1671-170X.2024.09.B001 |
|
 |
| 中文关键词: 非小细胞肺癌 甲磺酸伏美替尼 表皮生长因子受体 酪氨酸激酶抑制剂 |
| 英文关键词:non-small cell lung cancer furmonertinib epidermal growth factor receptor tyrosine kinase inhibitor |
| 基金项目:希思科-艾力斯肺癌靶向治疗研究基金项目（2021年度） |
|
| 摘要点击次数: 153 |
| 全文下载次数: 49 |
| 中文摘要: |
| 摘 要：非小细胞肺癌（non-small cell lung cancer，NSCLC）约占肺癌的80%~85%，表皮生长因子受体（epidermal growth factor receptor，EGFR）基因突变是最常见的驱动基因突变。EGFR酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitor，EGFR-TKI)是EGFR敏感突变晚期NSCLC患者的一线标准治疗。甲磺酸伏美替尼是我国自主研发的第三代 EGFR-TKI，具有双活性、高选择、强效缩瘤以及安全性好的特点。目前甲磺酸伏美替尼在治疗EGFR T790M突变、EGFR敏感突变、EGFR 外显子20插入突变以及中枢神经系统转移NSCLC均显示出确切的疗效。与此同时，围手术期治疗和三代EGFR-TKI耐药后采用甲磺酸伏美替尼再挑战的相关探索和研究也日益广泛。全文就甲磺酸伏美替尼在EGFR突变NSCLC治疗中的最新进展和临床研究进行综述，以期为甲磺酸伏美替尼临床应用提供更多参考。 |
| 英文摘要: |
| Abstract：Non-small cell lung cancer(NSCLC) accounts for 80%~85% of lung cancer cases， and epidermal growth factor receptor(EGFR) gene mutations are the most common driver mutations in NSCLC. EGFR-tyrosine kinase inhibitors(EGFR-TKI) have been the standard first-line treatment for advanced NSCLC with EGFR-sensitive mutations. Furmonertinib is a third-generation EGFR-TKI developed in China， characterized by dual activity， high selectivity， strong tumor shrinkage effects and good safety. Furmonertinib has demonstrated definite efficacy in the treatment of NSCLC with EGFR T790M mutation， EGFR-sensitive mutation， EGFR exon 20 insertion mutation and central nervous system metastasis. Meanwhile， exploration and research on perioperative treatment and rechallenge with furmonertinib after resistance to third-generation EGFR-TKI are also increasingly prevalent. This paper reviews the progress and clinical studies on the use of furmonertinib in the treatment of EGFR-mutated NSCLC to provide refe-rence for its clinical application. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |